Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XMaS: Xanthohumol in Healthy Adults
NCT03735420Phase 1Active, not recruiting
- Sponsor
- National University of Natural Medicine
- Start
- Aug 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing Xanthohumol with Placebo (2 arms). Primary endpoints: Change in Plasma Inflammatory Markers at 8 weeks and Incidence of Intervention-attributable Adverse Events at 8 weeks. Started Aug 2019; status: active, not recruiting.
02
Drugs
xanthohumol
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03735420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735420.